Obinutuzumab

Overview

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer and active lupus nephritis. It was originated by GlycArt Biotechnology AG and developed by Roche.[1–4] WP

Uses, dosage and effects

Medical uses

Obinutuzumab is indicated in combination with chlorambucil, for the treatment of people with previously untreated chronic lymphocytic leukemia; in combination with bendamustine followed by obinutuzumab monotherapy, for the treatment of people with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen; in combination with chemotherapy followed by obinutuzumab monotherapy in people achieving at least a partial remission, for the treatment of adults with previously untreated stage II bulky, III or IV follicular lymphoma; for the treatment of adults with active lupus nephritis who are receiving standard therapy.[1][5] WP

In September 2026, the indication was explanded to include the reduction of the risk of relapse in people aged two years of age and older with frequently relapsing or steroid-dependent, childhood-onset, idiopathic nephrotic syndrome who are in remission.[6] WP

Idiopathic nephrotic syndrome is a kidney disorder of unknown cause. In these patients, large amounts of protein leak into the urine, leading to low blood albumin levels (a type of protein in the blood) and often swelling. Idiopathic nephrotic syndrome can also lead to high cholesterol and other complications such as infections, and blood clots that can block small blood vessels. Idiopathic nephrotic syndrome is the most common cause of nephrotic syndrome in children and usually starts between 2-7 years of age. The annual incidence is estimated to be 1 to 4 per 100,000 children and varies with age, race, and geography.[6] WP

Risks and side effects

Side effects

The US prescription label has a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (a rare and serious brain infection caused by a virus in people with a weakened immune system).[6] WP

The most common side effects in people with idiopathic nephrotic syndrome are infections, infusion-related reactions, and neutropenia (low number of a type of white blood cell that fights infections).[6] WP

In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each). More than 20% of subjects had abnormal lab tests including low calcium and sodium, high potassium, increases in serum creatinine and liver function tests, and low albumin levels.[7] WP

Obinutuzumab was not tested in pregnant women.[1] WP

Research

Chronic lymphocytic leukemia

As of 2014 clinical trials had been conducted exploring the use of obinutuzumab as a second line monotherapy in relapsed/refractory chronic lymphocytic leukemia, as a monotherapy for relapsed/refractory non-Hodgkin lymphoma in people who had high expression of CD20; and in combination with CHOP chemotherapy as a first line treatment for people with advanced CD20-positive diffuse large B-cell lymphoma. It was called GA101 during research.[8][9] WP⚠ Wikipedia itself has flagged this text: citation needed.

Nephropathies

Obinutuzumab is recently reported to be safe and effective in some autoimmune diseases affecting the kidneys. It is a promising treatment of renal diseases with proteinuria, in particular patients with resistance or partial response to rituximab. A single low-dose infusion of obinutuzumab, found to be effective and safe in inducing prolonged remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. This effect is particularly shown in children who have rituximab resistance or relapse after rituximab. The tolerance profile of obinutuzumab is comparable to rituximab. Similar promising results is shown in adults with membranoproliferative glomerulonephritis treated with obinutuzumab after resistance to rituximab, tacrolimus and cyclophosphamide. Furthermore, obinutuzumab showed sustained clinical benefit through 2 years in patients with class III and IV Proliferative Lupus Nephritis compared to rituximab.[10][11] WP

History

History

Obinutuzumab was created by scientists at GlycArt Biotechnology, which had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich to develop afucosylated monoclonal antibodies; GA101 was one of its lead products when it was acquired by Roche in 2005.[8][12][13] WP

Roche developed the drug in the US through its subsidiary, Genentech, and in Japan through its subsidiary, Chugai. Genentech partnered with Biogen Idec to explore the use of the drug for primary biliary cirrhosis but as of 2014 it appeared the development in that indication had halted.[8] WP

In November 2013, the US Food and Drug Administration (FDA) approved obinutuzumab in combination with chlorambucil as a first-line treatment for chronic lymphocytic leukemia, and was the first drug with breakthrough therapy designation to gain approval.[14][15] WP

In October 2014, NICE announced that NHS England would not fund use of the drug, due to data uncertainties in Roche's application. In June 2015, NICE announced that it would fund restricted use of the drug.[16][17] WP

In their final recommendation of obinutuzumab, in the January 2015 Pan-Canadian Oncology Drug Review (pERC) for treatment of chronic lymphocytic leukemia, published by the Canadian Agency for Drugs and Technologies in Health, the list price of obinutuzumab provided by the manufacturer Hoffmann-La Roche was $CDN 5,275.54 per 1,000 mg vial. At the recommended dose obinutuzumab costs $15,826.50" for the first 28-day cycle and "$5275.50 per 28 day cycle for subsequent cycles."[18] WP

In February 2016, obinutuzumab was approved by the FDA under the Priority Review program for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of people with follicular lymphoma as a secondline treatment to a regimen containing rituximab.[5] WP

In January 2019, the FDA approved ibrutinib in combination with obinutuzumab for people with chronic lymphocytic leukemia/small lymphocytic lymphoma who have not received prior treatment.[19] WP

In October 2025, the FDA approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, making it the first anti-CD20 monoclonal antibody approved for this indication.[3] WP

In September 2026, it was approved to reduce the risk of relapse in people aged two years of age and older with frequently relapsing or steroid-dependent, childhood-onset, idiopathic nephrotic syndrome who are in remission. The efficacy and safety of obinutuzumab for treating nephrotic syndrome were evaluated in INSHORE (NCT05627557), a phase III, randomized, controlled, open-label, multi-center study in 85 participants aged two years of age and older with childhood-onset frequently relapsing or steroid-dependent idiopathic nephrotic syndrome. Participants had to be in complete remission at study entry, meaning no swelling and urine protein within the normal range. The application for obinutuzumab received breakthrough therapy, orphan drug, and priority review designations for this approval.[6] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Gazyva- obinutuzumab injection, solution, concentrate. 7 April 2020
2. Journal / agency Gazyvaro EPAR. 5 October 2023
3. Other Brooks A. FDA Approves Obinutuzumab (Gazyva) for Lupus Nephritis. 20 October 2025
4. Journal / agency Bronson J, Black A, Dhar M, Ellsworth B, Merritt JR. Annual Reports in Medicinal Chemistry. 2014. doi:10.1016/b978-0-12-800167-7.00027-4
5. Journal / agency Obinutuzumab. 26 February 2016
6. Journal / agency FDA Approves Drug to Treat Idiopathic Nephrotic Syndrome in Patients 2 Years and Older. 25 September 2026
7. Journal / agency Evans SS, Clemmons AB. Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia. Journal of the Advanced Practitioner in Oncology. 2015. doi:10.6004/jadpro.2015.6.4.7 · PMID 26705497 · PMC4677809
8. Journal / agency Cameron F, McCormack PL. Obinutuzumab: first global approval. Drugs. January 2014. doi:10.1007/s40265-013-0167-3 · PMID 24338113
9. Journal / agency Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. June 2010. doi:10.1182/blood-2009-06-225979 · PMID 20194898 · PMC2881503
10. Journal / agency Basu B, Angeletti A, Islam B, Ghiggeri GM. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?. Frontiers in Immunology. 11 February 2022. doi:10.3389/fimmu.2022.805697 · PMID 35222385 · PMC8873567
11. Journal / agency Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology. December 2023. doi:10.2215/cjn.0000000000000288 · PMID 37678236 · PMC10723910
12. Other Roche - Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research
13. Other Jean-Mairet J. Presentation: GlycArt Biotechnology AG From Inception to trade sale – and what happened after. 31 March 2011
14. Journal / agency FDA approves Gazyva for chronic lymphocytic leukemia: Drug is first with breakthrough therapy designation to receive FDA approval. 13 November 2013
15. Other F.D.A. Clears New Cancer-Fighting Drug From Roche. 2 November 2013
16. Other NICE denies Roche cancer drug due to 'data uncertainties'. 3 October 2014
17. Other NICE technology appraisal guidance (TA343). 2 June 2015
18. Other Final Recommendation for Obinutuzumab (Gazyva) for CLL Pan-Canadian Oncology Drug Review (pERC) Meeting: December 18, 2014; Early Conversion: pCODR. 27 January 2015
19. Other FDA Approves Ibrutinib/Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.